Pre-market negotiation: what made the JUPW share drop 9%?



Shares of Jupiter Wellness Inc. (JUPW) fell -9.46% to $ 4.02 during the last check in today’s pre-market session. During the weekend trading session, Jupiter Wellness stock gained 12.98% to $ 4.44 per share. JUPW stock averaged 0.98 million shares traded that day, above the last 50-day average volume of 0.14 million shares.

Over the past five days, JUPW shares have fallen -0.67% and over the past month they have fallen -3.27%. Over the past three months, the JUPW share price has fallen -11.02%. Following the conclusion of an exclusive licensing agreement, the JUPW share gained ground in the last session, but is losing ground today.

Which product is JUPW licensed in?

In addition to developing skin care products, Jupiter Wellness also offers skin care. JUPW’s product portfolio includes the endocannabinoid system as part of its improved therapeutic skin treatments, which target eczema, burns, cold sores and skin cancer indications. JUPW generates revenue from a growing line of private skin care and wellness products, including CaniSun sunscreen. JUPW’s website sells other wellness brands.

In an exclusive licensing agreement announced on Friday, Jupiter Wellness is authorized to market Photocil, a new topical cream that fights psoriasis, vitiligo and atopic dermatitis.

  • A license agreement signed between JUPW and Applied Biology (“AB”) makes JUPW the exclusive licensee of Photocil in the United States
  • In the Agreement, JUPW has access to the copyrights, patents, technology, know-how, trademarks, trade secrets, trademark applications and trade names of AB related to the use of Photocil by JUPW.
  • The rights granted to JUPW to use the intellectual property exclusively authorize the company to manufacture, market, advertise, promote and distribute Photocil for the treatment of skin conditions, including psoriasis and vitiligo.
  • In Europe, Asia and the Middle East, Photocil is already available under the names Presilux and MediSun.
  • JUPW expands and complements its strategy for treating skin diseases such as eczema, psoriasis and vitiligo through the license of Photocil.
  • An atopic dermatitis clinical trial involving JW-100, the new topical formulation of JUPW containing CBD and aspartame, showed a significant reduction in ISGA scores after two weeks in 50% of patients.
  • When the skin is exposed to direct sunlight, Photocil cream acts as a barrier against non-therapeutic radiation.
  • Thanks to the barrier of Photocil cream, daytime self-treatment with therapeutic (beneficial) UV radiation from the sun, commonly known as phototherapy, can be performed safely and effectively.
  • Photocil cream replaced the UV photo lamp, which was used for phototherapy before the advent of Photocil cream.

Jupiter Wellness Plan for Photocil:

Licenses for Photocil will allow Jupiter Wellness (JUPW) to offer additional treatment options to patients with skin conditions or seeking AM / PM or combination therapies. After FDA registration and approval, JUPW plans to market Photocil immediately.


Leave A Reply

Your email address will not be published.